重组人脑利钠肽对急性心肌梗死伴心衰患者的临床效果观察

Clinical observation of recombinant human brain natriuretic peptide in the patients with acute myocardial infarction complicated with heart failure

目的探讨重组人脑利钠肽治疗急性心肌梗死伴心衰患者的临床效果。方法 对2013年5月-2016年1月期间来我院治疗的急性心肌梗死伴心衰患者110例进行分析,将其按照随机数字表法分为两组,研究组和对照组各55例,两组患者均给予常规治疗,在常规治疗的基础上,研究组使用重组人脑利钠肽治疗,比较两组心功能疗效、LVEF、LVDd、NT-proBNP、hs-CRP。结果 与对照组比较,研究组在心功能方面的总有效率更高（P〈0.05）。治疗后两组LVEF升高,研究组与治疗前比较差异有统计学意义（P〈0.05）;治疗后两组LVDd与治疗前比较差异均无统计学意义（P〉0.05）。治疗后两组NT-proBNP、hs-CRP水平均明显降低,研究组NT-proBNP、hsCRP水平与对照组比较降低的程度更大（P〈0.05）。结论 急性心肌梗死伴心衰患者采用重组人脑利钠肽治疗疗效确切,可有效缓解患者的临床症状体征,使心功能得到有效改善,可在临床推广应用。

Objective To investigate the clinical efficacy of recombinant human brain natriuretic peptide in the patients with acute myocardial infarction complicated with heart failure. Methods A total of 110 patients with acute myocardial infarction complicated with heart failure who received treatment in our hospital from May 2013 to January 2016 were collected and analyzed. According to the random number table, they were divided into the study group and the control group, with 55 cases in each group. Two groups of patients were given conventional treatment. On the basis of the con- ventional treatment, the patients in the study group were treated with recombinant human brain natriuretic peptide, and the cardiac function, LVEF, LVDd, NT-proBNP and hs-CRP were compared between the two groups. Results The total effective rate in the study group was higher than that in the control group（P〈0.05）. After treatment, LVEF was increased in the two groups, and the difference in the study group was statistically significant compared to that before the treatment（P〈0.05）; there was no significant difference of LVDd after the treatment compared with that before treatment in the two groups（P〉0.05）. After treatment, the levels of NT-proBNP and hs-CRP in the two groups were significantly de- creased. The levels of NT-proBNP and hs-CRP in the study group were significantly lower than those in the control group（P〈0.05）. Conclusion The therapeutic effect of recombinant human brain uatriuretic peptide in the patients with acute myocardial infarction complicated with heart failure can effectively relieVe the clinical symptoms and signs of the patients, so that cardiac function can be effectively improved, which is worthy of clinical promotion and application.